The firm's CEO expects lab capital expenditures to return to normal by the second half of 2026 as the overall life science ...

The US Court of Appeals for the Federal Circuit remanded the case to the Patent Trial and Appeal Board to consider patent validity.

The agreement will enable Beijing-based RocGene to distribute its qPCR systems, reagents, and consumables in South Korea and to explore additional market strategies.

The company said that preliminary Q4 revenue was up 39 percent year over year and full-year 2025 revenue increased 35 percent ...

The autoimmune diagnostic company expects its new assay to be available by the end of this year or in early 2027.

Last week, readers were most interested in a story about the continued lack of clarity around Siemens Healthineers' diagnostics business at JP Morgan.

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The agency cleared lab-based and point-of-care infectious disease and clinical chemistry tests as well as software for digital pathology.

In addition to pushing cuts off until the beginning of 2027, the bill would update the data collection period used to establish the 2027 lab rates from 2019 to 2025.

The firm's benchtop TruVerus system can now run a total of 26 FDA-cleared assays in three modalities from a single blood collection tube.

The company's full-year 2025 revenues rose 6 percent year over year, with a 4 percent decline in diagnostics for the year.

The trial is being run by the Global Alzheimer's Platform Foundation in partnership with the UK Dementia Research Institute.